Advanced bronchioloalveolar carcinoma: A phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): A Southwest Oncology Group study

Howard L. West, J. J. Crowley, R. B. Vance, W. A. Franklin, R. B. Livingston, S. R. Dakhil, J. K. Giguere, S. E. Rivkin, M. Kraut, K. Chansky, David R Gandara

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background: There are no published prospective trials of chemotherapy for advanced bronchioloalveolar carcinoma (BAC), a subtype of non-small-cell lung cancer for which there is no current standard therapy. This phase II study assesses the efficacy and toxicity of 96-h paclitaxel in chemotherapy-naive patients with advanced BAC. Patients and methods: Patients with histologically confirmed stage IIIB (with pleural effusion) or stage IV BAC were eligible. Treatment consisted of paclitaxel 35 mg/m2/24 h continuously infused over 96 h (days 1-4) every 21 days for up to six courses. Results: A total of 58 eligible patients were enrolled. The objective response rate was 14% (all partial responses, 9% confirmed); 40% of patients demonstrated stable disease. The median progression-free and overall survivals were 5 and 12 months, respectively. Grade 3 or greater toxicities included neutropenia/granulocytopenia (43%), febrile neutropenia (12%), infection (22%), and stomatitis/pharyngitis (10%); there were five treatment-related deaths. Conclusions: S9714 represents the first prospective multi-institutional cooperative group trial focusing on treatment outcomes in BAC. Studies targeting this population are feasible, and while first-line paclitaxel administered as a prolonged infusion is active in this setting, toxicities limits the utility of this regimen. S9714 serves as a historical control for BAC patients against which future therapeutic approaches can be compared.

Original languageEnglish (US)
Pages (from-to)1076-1080
Number of pages5
JournalAnnals of Oncology
Volume16
Issue number7
DOIs
StatePublished - Jul 2005

Fingerprint

Bronchiolo-Alveolar Adenocarcinoma
Paclitaxel
Drug Therapy
Febrile Neutropenia
Stomatitis
Agranulocytosis
Pharyngitis
Pleural Effusion
Therapeutics
Neutropenia
Non-Small Cell Lung Carcinoma
Disease-Free Survival
Infection
Population

Keywords

  • Bronchioloalveolar carcinoma
  • Non-small lung cancer
  • Paclitaxel
  • Prolonged infusion

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Advanced bronchioloalveolar carcinoma : A phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): A Southwest Oncology Group study. / West, Howard L.; Crowley, J. J.; Vance, R. B.; Franklin, W. A.; Livingston, R. B.; Dakhil, S. R.; Giguere, J. K.; Rivkin, S. E.; Kraut, M.; Chansky, K.; Gandara, David R.

In: Annals of Oncology, Vol. 16, No. 7, 07.2005, p. 1076-1080.

Research output: Contribution to journalArticle

West, HL, Crowley, JJ, Vance, RB, Franklin, WA, Livingston, RB, Dakhil, SR, Giguere, JK, Rivkin, SE, Kraut, M, Chansky, K & Gandara, DR 2005, 'Advanced bronchioloalveolar carcinoma: A phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): A Southwest Oncology Group study', Annals of Oncology, vol. 16, no. 7, pp. 1076-1080. https://doi.org/10.1093/annonc/mdi215
West, Howard L. ; Crowley, J. J. ; Vance, R. B. ; Franklin, W. A. ; Livingston, R. B. ; Dakhil, S. R. ; Giguere, J. K. ; Rivkin, S. E. ; Kraut, M. ; Chansky, K. ; Gandara, David R. / Advanced bronchioloalveolar carcinoma : A phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): A Southwest Oncology Group study. In: Annals of Oncology. 2005 ; Vol. 16, No. 7. pp. 1076-1080.
@article{c08b8c0439fc40d8a8f5e75357f71ed3,
title = "Advanced bronchioloalveolar carcinoma: A phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): A Southwest Oncology Group study",
abstract = "Background: There are no published prospective trials of chemotherapy for advanced bronchioloalveolar carcinoma (BAC), a subtype of non-small-cell lung cancer for which there is no current standard therapy. This phase II study assesses the efficacy and toxicity of 96-h paclitaxel in chemotherapy-naive patients with advanced BAC. Patients and methods: Patients with histologically confirmed stage IIIB (with pleural effusion) or stage IV BAC were eligible. Treatment consisted of paclitaxel 35 mg/m2/24 h continuously infused over 96 h (days 1-4) every 21 days for up to six courses. Results: A total of 58 eligible patients were enrolled. The objective response rate was 14{\%} (all partial responses, 9{\%} confirmed); 40{\%} of patients demonstrated stable disease. The median progression-free and overall survivals were 5 and 12 months, respectively. Grade 3 or greater toxicities included neutropenia/granulocytopenia (43{\%}), febrile neutropenia (12{\%}), infection (22{\%}), and stomatitis/pharyngitis (10{\%}); there were five treatment-related deaths. Conclusions: S9714 represents the first prospective multi-institutional cooperative group trial focusing on treatment outcomes in BAC. Studies targeting this population are feasible, and while first-line paclitaxel administered as a prolonged infusion is active in this setting, toxicities limits the utility of this regimen. S9714 serves as a historical control for BAC patients against which future therapeutic approaches can be compared.",
keywords = "Bronchioloalveolar carcinoma, Non-small lung cancer, Paclitaxel, Prolonged infusion",
author = "West, {Howard L.} and Crowley, {J. J.} and Vance, {R. B.} and Franklin, {W. A.} and Livingston, {R. B.} and Dakhil, {S. R.} and Giguere, {J. K.} and Rivkin, {S. E.} and M. Kraut and K. Chansky and Gandara, {David R}",
year = "2005",
month = "7",
doi = "10.1093/annonc/mdi215",
language = "English (US)",
volume = "16",
pages = "1076--1080",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Advanced bronchioloalveolar carcinoma

T2 - A phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): A Southwest Oncology Group study

AU - West, Howard L.

AU - Crowley, J. J.

AU - Vance, R. B.

AU - Franklin, W. A.

AU - Livingston, R. B.

AU - Dakhil, S. R.

AU - Giguere, J. K.

AU - Rivkin, S. E.

AU - Kraut, M.

AU - Chansky, K.

AU - Gandara, David R

PY - 2005/7

Y1 - 2005/7

N2 - Background: There are no published prospective trials of chemotherapy for advanced bronchioloalveolar carcinoma (BAC), a subtype of non-small-cell lung cancer for which there is no current standard therapy. This phase II study assesses the efficacy and toxicity of 96-h paclitaxel in chemotherapy-naive patients with advanced BAC. Patients and methods: Patients with histologically confirmed stage IIIB (with pleural effusion) or stage IV BAC were eligible. Treatment consisted of paclitaxel 35 mg/m2/24 h continuously infused over 96 h (days 1-4) every 21 days for up to six courses. Results: A total of 58 eligible patients were enrolled. The objective response rate was 14% (all partial responses, 9% confirmed); 40% of patients demonstrated stable disease. The median progression-free and overall survivals were 5 and 12 months, respectively. Grade 3 or greater toxicities included neutropenia/granulocytopenia (43%), febrile neutropenia (12%), infection (22%), and stomatitis/pharyngitis (10%); there were five treatment-related deaths. Conclusions: S9714 represents the first prospective multi-institutional cooperative group trial focusing on treatment outcomes in BAC. Studies targeting this population are feasible, and while first-line paclitaxel administered as a prolonged infusion is active in this setting, toxicities limits the utility of this regimen. S9714 serves as a historical control for BAC patients against which future therapeutic approaches can be compared.

AB - Background: There are no published prospective trials of chemotherapy for advanced bronchioloalveolar carcinoma (BAC), a subtype of non-small-cell lung cancer for which there is no current standard therapy. This phase II study assesses the efficacy and toxicity of 96-h paclitaxel in chemotherapy-naive patients with advanced BAC. Patients and methods: Patients with histologically confirmed stage IIIB (with pleural effusion) or stage IV BAC were eligible. Treatment consisted of paclitaxel 35 mg/m2/24 h continuously infused over 96 h (days 1-4) every 21 days for up to six courses. Results: A total of 58 eligible patients were enrolled. The objective response rate was 14% (all partial responses, 9% confirmed); 40% of patients demonstrated stable disease. The median progression-free and overall survivals were 5 and 12 months, respectively. Grade 3 or greater toxicities included neutropenia/granulocytopenia (43%), febrile neutropenia (12%), infection (22%), and stomatitis/pharyngitis (10%); there were five treatment-related deaths. Conclusions: S9714 represents the first prospective multi-institutional cooperative group trial focusing on treatment outcomes in BAC. Studies targeting this population are feasible, and while first-line paclitaxel administered as a prolonged infusion is active in this setting, toxicities limits the utility of this regimen. S9714 serves as a historical control for BAC patients against which future therapeutic approaches can be compared.

KW - Bronchioloalveolar carcinoma

KW - Non-small lung cancer

KW - Paclitaxel

KW - Prolonged infusion

UR - http://www.scopus.com/inward/record.url?scp=25444442802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444442802&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdi215

DO - 10.1093/annonc/mdi215

M3 - Article

C2 - 15860488

AN - SCOPUS:25444442802

VL - 16

SP - 1076

EP - 1080

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -